TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03372109

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal replacement shake
Description: Meal replacement shake taken two days per week during the modified fasting periods

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin and mineral capsules
Description: Multivitamin/mineral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil with sesame lignans and olive extract softgel
Description: Wild Fish Oil Concentrate 2000mg, Olive Extract 300mg, Sesame seed lignan extract 10mg/2 softgels

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic Chewable tablet
Description: Prebiotic Fiber 1,400 mg/tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Clove Extract and Maqui Berry extract capsule
Description: Clove extract 250mg and maqui berry extract 200mg/capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: .Whole Food Blend capsule
Description: Whole food blend 1000mg/3 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric extract capsule
Description: Turmeric 25:1 extract 400mg/capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: European White Kidney Bean capsule
Description: White kidney bean extract 100mg/capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saffron extract capsule
Description: Saffron extract 88.25mg/capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ubiquinol with Fulvic acid complex softgel
Description: Ubiquinol 100mg and Fulvic Acid complex 100mg/softgel

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium with Hesperidin and gynostemma extract tablet
Description: Calcium 130mg. hesperidin 500mg and gynostemma extract 450mg/ tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin and mineral supplement
Description: Multivitamin and multimineral supplement
Study: NCT04615468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525
Description: TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
Study: NCT00041301

Intervention type: OTHER
Intervention: QoL assessment
Description: qol questionnaires
Study: NCT01265615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: paricalcitol group (6-8 μg daily per os - orally - without special diet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Supplemental
Description: intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
Study: NCT00729482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 (everolimus) 10mg daily administration orally until disease progression and/or intolerability
Study: NCT02551614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide challenge
Description: Lipopolysaccharide solution inhaled using a dosimeter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline challenge
Description: 0.9% sodium chloride solution inhaled using dosimeter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Labelled neutrophils and Imaging assessment
Description: Injection of labelled neutrophils and imaging assessments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Labelled neutrophils and Imaging assessment
Description: Injection of labelled neutrophils and imaging assessments
Study: NCT02489643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized practical training
Study: NCT00006469

Intervention type: DRUG
Group type: OTHER
Intervention: carboplatin

Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: neoadjuvant therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study: NCT02600104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWayTM
Description: The PicoWayTM base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier
Study: NCT04234672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Oral Tablet
Description: TAK-831 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TAK-831 IV Infusion
Description: \[14C\]TAK-831 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TAK-831 Oral Suspension
Description: \[14C\]TAK-831 oral suspension.
Study: NCT04354909

Intervention type: OTHER
Intervention: s-CD95-L
Description: levels of s-CD95-L (ELISA test)
Study: NCT02056197

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Shortwave

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable surface exercises
Description: Stable surface exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unstable surface exercises
Study: NCT01810653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macrogol (Transipeg, BAY81-8430)
Description: Up to 4 sachets per day based on individual titration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol (Forlax)
Description: Up to 4 sachets per day based on individual titration
Study: NCT00842231

Intervention type: OTHER
Intervention: Visual performance measures
Description: Collection of visual performance measures in subjects with low levels of astigmatism.
Study: NCT03469583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001
Description: EYP001 self administered capsules, morning, with non carbonated water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001
Description: EYP001 self administered capsules, morning, with non carbonated water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir 1 MG
Description: Entecavir self administered tablets, morning, with non carbonated water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir 1 MG
Description: Entecavir self administered tablets, morning, with non carbonated water
Study: NCT04329351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided Bone regeneration
Description: Guided bone regeneration to ridge preservation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Guided Bone regeneration
Description: Guided bone regeneration to ridge preservation
Study: NCT00659620

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: transplantation of mesenchymal stem cell
Study: NCT02153554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training civil servants on attention to violence against women
Description: The Secretary of Women of Medellin, through the ICONTEC, intends to conduct training to officials of the 22 family commissioners in Medellin. The objective of these trainings is to standardize procedures in order that women do not feel re-victimized and can forward complaints.
Study: NCT01141036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol will be initiated with a 30-50 mg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
Study: NCT04512443

Intervention type: DRUG
Intervention: Daflon
Description: All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
Study: NCT01723215

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active ABMT8
Description: Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active ABMT4
Description: Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
Study: NCT02706704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Study: NCT01053442

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porridge fortified with either NaFeEDTA
Description: 265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4
Description: Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
Study: NCT01316185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP921
Description: Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP921
Description: Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.
Study: NCT00713479

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline, then placebo
Description: Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline, then placebo
Description: Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, then varenicline
Description: Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, then varenicline
Description: Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
Study: NCT00510081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxylapatite injection
Description: filler injection
Study: NCT00888420

Intervention type: OTHER
Intervention: Performance Improvement Measures
Description: PDSA (Plan, Do, Study, Act) performance improvement measures
Study: NCT02844920

Intervention type: DEVICE
Intervention: Intrauterine ultrasound guided radio-frequency ablation
Description: Radiofrequency ablation for the treatment of uterine fibroids
Study: NCT02307487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg MMC in 90ml gel
Description: 120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg MMC in 90ml gel
Description: 140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 mg MMC in 90ml gel
Description: 160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg MMC in 60ml gel
Description: 120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg MMC in 60ml gel
Description: 140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 mg MMC in 60ml gel
Description: 160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
Study: NCT00227292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10mg per day for the first week, then 20mg per day till the end of study.
Study: NCT02562079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: * biological features of the standard follow-up~* 2 more blood tube for the biological collection (serum and PBMC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: * biological features of the standard follow-up~* 2 more blood tube for the biological collection (serum and PBMC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: * biological features of the standard follow-up~* 2 more blood tube for the biological collection (serum and PBMC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Skin biopsies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Skin biopsies
Study: NCT01087099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Treatment with albendazole
Study: NCT01214694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT)
Description: Families in I-InTERACT will view 10 web-sessions (like chapters) and participate in 27 family meetings over the course of 24 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
Study: NCT04139213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral naltrexone
Description: To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
Study: NCT01214694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express)
Description: Families in I-InTERACT Express will view 10 web-sessions (like chapters) and participate in 14 family meetings over the course of 7 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Resources Comparison (IRC)
Description: Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
Study: NCT01743924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: raw broccoli
Description: To eat this plant material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: raw broccoli
Description: To eat this plant material
Study: NCT02486653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: tamsulosin 0.4mg in the evening~* Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: placebo in the evening~* Day 8: surgery; placebo in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: placebo in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function.
Study: NCT04049955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
Study: NCT00612170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Description: 10 mg oral tablet once a day dosing

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: 0 mg oral tablet once a day dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Description: 4 mg oral tablet once a day dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Description: 8 mg oral tablet once a day dosing
Study: NCT02427451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bcl-2 Inhibitor GDC-0199
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02193321

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Patch
Study: NCT01127659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone
Description: intramuscular every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone
Description: intramuscular every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline intramuscular every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline intramuscular every 2 weeks
Study: NCT04637607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupoints stimulation
Description: Noninvasive auricular acupoints stimulation with seeds

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Auricular acupoints stimulation
Description: Noninvasive auricular acupoints stimulation with seeds
Study: NCT00047671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: PDA Approved antidepressant
Study: NCT00699465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: enoxaparin placebo
Description: Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.
Study: NCT00825279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Stent
Description: Stainless steel stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent
Description: stent coated with the biodegradable polymer matrix hemoparin and paclitaxel
Study: NCT00502814

Intervention type: PROCEDURE
Intervention: 3-D Optical Surface Scan
Description: 3-D digitized images of the breasts and chest will be taken over a period of five minutes.

Intervention type: PROCEDURE
Intervention: Mechanical Testing
Description: A small device with a mild suction will be used to measure how the skin tends to stretch.

Intervention type: PROCEDURE
Intervention: Cutaneous Ultrasound
Description: Cutaneous ultrasound using a 20 MHz machine and the skin thickness will be recorded.

Intervention type: PROCEDURE
Intervention: Breast MRI and/or CT
Description: Imaging of the breasts and chest using an MRI and/or CT scan over about one hour.
Study: NCT04350385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agility training
Description: In experimental group, 30 meter sprint test will be used as intervention with complexity in different stages. Test 1 was a straight sprint and tests 2-7 involved multiple changes of direction. Tests 2-7 were designed to involve progressively greater change-of-direction complexity by increasing either the angle of directional change and/or the number of changes of direction. In experimental group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd \& 6th week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: In group B, Conventional intervention was given to the players under the supervision of Physical Therapist that includes warm-up, strength training, agility training and cool down. In control group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd \& 6th week